]>
IRCT138807252394N2 IRCT 2010-03-13 Iran Univesity of Medical Sciences Effects of Quercetin on plasma total antioxidant capacity, lipid peroxidation, blood pressure, inflammatory markers and disease activity in patients with Rheumatoid Arthritis Effects of Quercetin on plasma total antioxidant capacity, lipid peroxidation, blood pressure, inflammatory markers and disease activity in patients with Rheumatoid Arthritis 2010-04-21 anticipated 50 Complete https://irct.ir/trial/2074 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. N/A Condition 1: Rheumatoid Arthritis. Condition 2: Rheumatoid arthritis. Intervention 1: Quercetin supplement, 500 mg caps per day for 8 weeks. Intervention 2: placebo caps for 8 weeks.
public
scientific Dr. Shima Jazayeri
School of Health, Alvand Ave, Arjantin Sq
Tehran Iran (Islamic Republic of) +98 21 8877 9118 s.jazayeri@iums.ac.ir School of Health, Iran University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Inclusion criteria: Willing to participate in study, Clinical diagnosis of AR (meeting the American college of rheumatology 1987 criteria), Ages between 19 – 70 years , No smoking or addiction , No drug type and dose fluctuation since 1 month prior to the study and during intervention period , Not having severe cardiovascular, hepatic, kidney, gastrointestinal, thyroid, parathyroid diseases, diabetes and inflammation, Not using medications except for AR conventional drugs, Not using antioxidant supplements during last month, No pregnancy or lactation Exclusion criteria: Compliance less than 70%, Disinclination to continue for cooperation, developing illnesses which need particular cures or interfere with intervention such as increasing the disease activity or trauma 19 years 70 years Both M05 M06 Seropositive rheumatoid arthritis Other rheumatoid arthritis Treatment - Drugs Quercetin supplement, 500 mg caps per day for 8 weeks placebo caps for 8 weeks Total antioxidant capacity (TAC). Timepoint: 8 weeks. Method of measurement: colorimetric assay. Hs-TNF-alpha. Timepoint: 8 weeks. Method of measurement: ELISA. Hs- CRP. Timepoint: 8 weeks. Method of measurement: ELISA. Ox-LDL. Timepoint: 8 weeks. Method of measurement: ELISA. Malondialdehyde. Timepoint: 8 weeks. Method of measurement: chemical colorimetric. Disease activity score- 28 joints(DAS-28). Timepoint: 8 weeks. Method of measurement: Physical examination. Morning stiffness. Timepoint: 8 weeks. Method of measurement: question. Blood pressure. Timepoint: 8 weeks. Method of measurement: sphyngomanometer. Rheumatoid factor(RF). Timepoint: 8 weeks. Method of measurement: turbidometric assay. Eritrocyte sedimentation rate(ESR). Timepoint: 8 weeks. Method of measurement: . Iran Univesity of Medical Sciences Approved Ethics committee of school of health, Iran university of medical sciences school of Health, Arjantin Square, Alvand Ave., Tehran Tehran Iran (Islamic Republic of)